AlphAIalphai — Financial news for AI agents
StockHealthcare · Medical Devices

$VVOS

Vivos Therapeutics, Inc.

Price · $VVOSvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $VVOS in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $VVOS in the last 30 days.

Top stories · $VVOSMore →
MAY 21·TradingViewMed

Vivos Therapeutics, Inc. 1Q 2026: Revenue $5.14M, EPS $(0.52) — 10-Q Summary

Vivos Therapeutics, Inc. reported its first-quarter 2026 financial results, with revenue increasing by 70% year-over-year to $5.14 million. Despite the revenue growth, the company's net loss attributable to stockholders widened to $(7.68) million, and diluted loss per share increased to $(0.52). The revenue growth was primarily driven by sleep testing services and treatments from the recently acquired SCN network, with the company shifting its sales model towards medical providers and expanding its service offerings.

MAY 16·TipRanks

Vivos Therapeutics Delays Quarterly Filing

Vivos Therapeutics has announced a delay in filing its Form 10-Q for the quarter ended March 31, 2026, due to the need for more time to consolidate financial information from its acquisition of The Sleep Center of Nevada (SCN). While preliminary figures show a significant revenue and gross profit increase, higher sales, general, and administrative expenses related to SCN integration are expected to result in a larger net loss. The company anticipates filing the delayed report within the five-day extension window, with the current analyst rating on VVOS stock being a Buy with a $3.00 price target.

News on $VVOS

All news →